Moberg Pharma AB (publ)
STO:MOB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.645
38.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Moberg Pharma AB (publ)
Moberg Pharma AB (publ)
Total Liabilities
Moberg Pharma AB (publ)
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Total Liabilities
kr24m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Total Liabilities
kr1.6B
|
CAGR 3-Years
85%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Total Liabilities
kr454.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Total Liabilities
kr2.4B
|
CAGR 3-Years
77%
|
CAGR 5-Years
152%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Total Liabilities
kr61.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Total Liabilities
kr26.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Total Liabilities?
Total Liabilities
24m
SEK
Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Total Liabilities amounts to 24m SEK.
What is Moberg Pharma AB (publ)'s Total Liabilities growth rate?
Total Liabilities CAGR 3Y
-36%
Over the last year, the Total Liabilities growth was -22%. The average annual Total Liabilities growth rates for Moberg Pharma AB (publ) have been -36% over the past three years .
You don't have any saved screeners yet
